Business Wire

Azbil Launches an Enhanced Thermal Micro Flow Rate Liquid Flow Meter Capable of Measuring Flows of 0.5 to 50 mL/min, Adds Functionality to Existing Lineup

Jaa

Azbil Corporation (TOKYO:6845) announced that it has enhanced its Thermal Micro Flow Rate Liquid Flow Meter Model F7M (hereafter, "F7M flow meter") lineup by introducing a model with an increased measurement range of up to 50 mL/min, while adding new functionality to existing models. Sales commenced in May.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190521006021/en/

Thermal Micro Flow Rate Liquid Flow Meter Model F7M (Photo: Business Wire)

Thermal Micro Flow Rate Liquid Flow Meter Model F7M (Photo: Business Wire)

Based on the company's years of experience bringing reliable gas flow meters to market, Azbil originally launched two models of the F7M flow meter in 2017, with one model capable of measuring micro flow rates as low as 0.1 mL/min—a level that was considered until that point to be difficult to measure. The company launched the new F7M flow meter and added functionality to the existing lineup in response to the ever diverse needs of customers and the limited availability of flow meters that measure micro flows up to 50 mL/min.

 
Overview
1.   New model features a measurement range of 0.5 to 50 mL/min. (The two existing models feature a range of 0.1 to 10 mL/min and 0.3 to 30 mL/min, respectively.)
2. During zero point adjustment, the flow meter estimates and automatically sets the correction value characteristic to each liquid. (All models)
3. A single unit can measure two types of liquids by switching between the respective liquid correction values upon receiving a digital contact signal from an external device. (All models)
 

Azbil enhanced all three models of the F7M flow meter to automatically set the correction value. This can be performed easily through button operation or the flow meter receiving a digital signal from a host device, eliminating the need for specialized knowledge or equipment.

Additionally, the F7M flow meter can save correction values for two types of liquids and switch between them by receiving a digital contact signal from a host device, allowing a single unit to measure the flow rate of both liquids.

Guided by the azbil Group philosophy of “human-centered automation,” Azbil is committed to delivering products that satisfy customers’ needs, providing safety, comfort, and fulfillment.

- For details, please visit the following website.
https://www.azbil.com/products/factory/factory-product/flowmeter/rate-liquid/index.html

About Azbil Corporation

Azbil Corporation is a leading company in building and industrial automation, using its measurement and control technologies to provide customers with high value-added solutions to make their operations more efficient and sustainable. Founded in 1906, Azbil serves customers across the globe in a broad range of industries and aims to contribute to people's safety, comfort and fulfillment, and global environmental preservation. At the end of March 2019, Azbil employed 9,600 people worldwide and generated JPY262 billion in revenue.
For more information, please visit https://www.azbil.com.

Contact information

For media inquiries
Robert Jones / Masayoshi Kogai
Public Relations Section, Azbil Corporation
Phone: +81-3-6810-1006 (Japan) Email: publicity@azbil.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors17.6.2019 19:00:00 EESTTiedote

Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors. The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T-lymphocyte checkpoint inhibitor. “We are very pleased with the progress achieved on BI 765063’s program and having the first patient dosed marks a significant milestone in the product’s development. The advancement of a myeloid cell checkpoint blocking monoclonal antibody into the clinic exemplifies Boehringer Ingelheim’s commitment to the next wave of innovation in cancer immunology therapies, with the goal of meaningfully improving outcomes fo

MagicStay Raises €3 Million to Accelerate Its International Development17.6.2019 18:58:00 EESTTiedote

The apartment rental platform dedicated to business travelers, MagicStay.com , announces its full integration into the main business travel booking tools and a €3 million A-series to pursue its development, bringing the amounts raised to more than €8 million since its launch in 2013. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005644/en/ William Lecerf and Valéry Linyer, co-founders of MagicStay (Photo: MagicStay) "This fundraising will allow us to recruit talent to accelerate our growth. We want to sign a quarter of the major French companies and approach one million homes before the end of the year, thanks to the exclusive technologies we now have at our disposal", says Valéry Linÿer, CEO and co-founder, who adds: "We have four main advantages over our competitors: we meet the challenges of duty of care, we are able to customize our tool to meet the constraints of each large company for short and long stays, we ha

EURid Shows a 94% Reduction of Its Footprint since 201217.6.2019 18:32:00 EESTTiedote

EURid, the not-for-profit organisation that operates the .eu and .ею top-level domains, is the first European TLD registry that registered for the EU Eco-Management and Audit Scheme (EMAS) from 2011. Since then, EURid has regularly assessed the environmental impact of its activities and monitored the compliance of its policies and procedures. As over the past four years, in Q2 2019 EURid was audited for the CO2 emissions of the previous year, resulting in an overall footprint of 135 tons CO2eq, which shows a 94% reduction since 2012. “We have achieved carbon neutrality via several actions and the compensation of the audited emissions. We were and are still among the first in our sector to report on our commitment to protect the environment”, commented CEO Marc Van Wesemael. Through EMAS, EURid has had the opportunity to support a multitude of global sustainability initiatives, like the Ugandan Borehole Project, Ecomapuà Project in the Amazon, the Dak Rung Hydropower Project in Vietnam,

Animation, Sound & Vibration – How Visa is Reinforcing Consumer Trust in a Changing Payments World17.6.2019 18:00:00 EESTTiedote

Visa (NYSE: V) today announced global adoption of its sensory branding suite in 25 countries via more than a dozen new partnerships. The suite is comprised of sound, animation and haptic brand cues that occur with a Visa payment transaction. In a digital world increasingly filled with voice-commands, networked appliances and unattended retail environments, Visa’s sensory branding cues offer new ways to enhance the customer experience and convey the trust and security that the Visa brand represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005240/en/ Visa was the first major payment brand to introduce multi-sensory branding, which included animation, sound and haptic vibration expressions of its brand. After an extensive creation and selection process that involved focus groups and elimination rounds, Visa landed on a single ‘energetic’ and ‘optimistic’ sound, and complementary animation and haptic vibration. Sinc

Study from Project Management Institute Identifies Six AI Technologies Impacting Project Professionals17.6.2019 17:40:00 EESTTiedote

Project Management Institute (PMI) today released its 2019 Pulse of the Profession® In-Depth Report: AI Innovators: Cracking the Code on Project Performance. The report provides an in-depth look at how artificial intelligence (AI) is impacting organizations and the project management profession. Findings reveal that AI disruption is happening and at a large scale: 81 percent of respondents report their organization is being impacted by AI technologies; 37 percent say adopting AI technologies is a high priority for their organization; and project professionals say they expect the proportion of the projects they manage using AI will jump from 23 to 37 percent over the next three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005558/en/ These insights from a survey of 551 project management practitioners globally show that the presence of AI technologies will continue to grow, requiring shifts in how projects are m

RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration17.6.2019 16:15:00 EESTTiedote

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD). SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD that was poorly responsive to previous intravitreal anti-VEGF therapy. Through the 56-Day exit visit, excluding one uncompleted case in the last cohort, single dose of RBM-007 demonstrated no dose-limiting toxicities, no systemic or ocular serious adverse events. One subject in Cohort 3 showed anterior inflammation, which was resolved after one day of topical prednisolone treatment. Rescue treatment with anti-VEGF therapy was ava

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme